Piroxicam

Sold as Feldene. Every FDA application for this active ingredient: 1 branded and 22 generic.

As of Nov 15, 2026, FDA lists 23 applications for Piroxicam (sold as Feldene), first approved Apr 6, 1982, with 0 new uses approved and 0 published complete response letters.

First approved: Apr 6, 1982
Applications: 23
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $1.9M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Piroxicam	Part D	$1.9M	-66%	14,744

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

PIROXICAM 10 MG CAPSULE: $0.156 per unitGeneric · -26% in a year
PIROXICAM 20 MG CAPSULE: $0.206 per unitGeneric · -3% in a year

Clinical Trials

6 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all


Rct Assessing Pregnancy - Piroxicam for Ec With LevonorgestrelEmergency Contraception, Contraception · University of Utah	Phase 3	Not yet recruiting	Mar 4, 2026
Comparison of the Pain Levels of Single-Dose Premedication With Piroxicam and Prednisolone on Post-Endodontic Pain in Single-Visit Root Canal Treatment of PremolarsIrreversible Pulpitis With Apical Periodontitis, Symptomatic Apical Periodontitis · RANA AHMAD	Phase 4	Not yet recruiting	Dec 15, 2025
Ultrasonication-mediated Microbubbles Dressing for Hand ArthritisHand Arthritis · National Taiwan University	Not applicable	Recruiting	Apr 6, 2025
Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency ContraceptionContraception · The University of Hong Kong	Phase 3	Recruiting	Dec 11, 2024
Oral NSAI Versus Acetaminophen or Placebo as a Discharge Treatment of Non Complicated Renal ColicsRenal Colic · University of Monastir	Phase 2	Recruiting	Feb 10, 2023
CHronic Nonbacterial Osteomyelitis International RegistryChronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis · Seattle Children's Hospital	—	Recruiting	Jan 26, 2021

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Apr 6, 1982	FeldeneNDA 18147 · New molecular entity	Pfizer	37	Marketed
May 29, 1992	PiroxicamANDA 74036	Scs	0	Discontinued
Jul 31, 1992	PiroxicamANDA 74102	Pharmobedient	7	Discontinued
Aug 28, 1992	PiroxicamANDA 74103	Teva Pharms	5	Discontinued
Sep 22, 1992	PiroxicamANDA 74043	Mylan	6	Discontinued
Dec 11, 1992	PiroxicamANDA 74131	Teva	16	Marketed
Mar 12, 1993	PiroxicamANDA 73536	Sun Pharm Industries	7	Discontinued
Jun 15, 1993	PiroxicamANDA 74118	Solis Pharms	7	Marketed
Jan 28, 1994	PiroxicamANDA 73637	Teva	3	Discontinued
Jan 28, 1994	PiroxicamANDA 73638	Teva	4	Discontinued
Sep 29, 1995	PiroxicamANDA 74460	Watson Labs	5	Discontinued
May 16, 1996	PiroxicamANDA 74287	Watson Labs	1	Discontinued
Jun 3, 1996	PiroxicamANDA 74148	Ivax Sub Teva Pharms	7	Discontinued
Jul 8, 1997	PiroxicamANDA 74808	Egis	1	Discontinued
Sep 9, 2016	PiroxicamANDA 207938	Flamingo Pharms	0	Discontinued
Apr 13, 2017	PiroxicamANDA 208340	Unichem	4	Discontinued
Jun 20, 2017	PiroxicamANDA 206136	Strides Pharma	5	Discontinued
Aug 11, 2017	PiroxicamANDA 209256	Hikma	3	Discontinued
Dec 29, 2017	PiroxicamANDA 206152	Micro Labs	5	Marketed
Jan 26, 2018	PiroxicamANDA 210347	Strides Pharma	5	Marketed
Feb 21, 2018	PiroxicamANDA 208991	Breckenridge	0	Discontinued
Jul 17, 2018	PiroxicamANDA 205585	Zydus Lifesciences	1	Marketed
—	PiroxicamANDA 73651	Cycle	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA